GRML
What one share of Greenland Mines holds
Biological Products, (No Diagnostic Substances)
On September 12, 2022, the Company acquired five market-approved anti-cancer drugs approved for sale in Germany. The Market Authorizations (MA’s) are for four of the drugs that comprise the “FOLFOX”
Greenland Mines’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.25 |
|---|---|
| Cash and investments | $0.06 |
| Book value | $0.36 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$0.05 | — | −$0.03 | $16.50 | −$0.03 |
| 2024 | — | −$0.32 | — | −$0.15 | — | $0.04 |
| 2025 | — | −$0.22 | — | −$0.12 | — | $0.13 |